Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea
AuthorEastwood, PR; Barnes, M; MacKay, SG; Wheatley, JR; Hillman, DR; Nguyen, X-L; Lewis, R; Campbell, MC; Petelle, B; Walsh, JH; ...
Source TitleEuropean Respiratory Journal
PublisherEUROPEAN RESPIRATORY SOC JOURNALS LTD
AffiliationMedicine and Radiology
Surgery (Austin & Northern Health)
Document TypeJournal Article
CitationsEastwood, P. R., Barnes, M., MacKay, S. G., Wheatley, J. R., Hillman, D. R., Nguyen, X. -L., Lewis, R., Campbell, M. C., Petelle, B., Walsh, J. H., Jones, A. C., Palme, C. E., Bizon, A., Meslier, N., Bertolus, C., Maddison, K. J., Laccourreye, L., Raux, G., Denoncin, K. ,... Launois, S. H. (2020). Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea. EUROPEAN RESPIRATORY JOURNAL, 55 (1), https://doi.org/10.1183/13993003.01320-2019.
Access StatusOpen Access
BACKGROUND AND AIM: Hypoglossal nerve stimulation (HNS) decreases obstructive sleep apnoea (OSA) severity via genioglossus muscle activation and decreased upper airway collapsibility. This study assessed the safety and effectiveness at 6 months post-implantation of a novel device delivering bilateral HNS via a small implanted electrode activated by a unit worn externally, to treat OSA: the Genio™ system. METHODS: This prospective, open-label, non-randomised, single-arm treatment study was conducted at eight centres in three countries (Australia, France and the UK). Primary outcomes were incidence of device-related serious adverse events and change in the apnoea-hypopnoea index (AHI). The secondary outcome was the change in the 4% oxygen desaturation index (ODI). Additional outcomes included measures of sleepiness, quality of life, snoring and device use. This trial was registered with ClinicalTrials.gov, number NCT03048604. RESULTS: 22 out of 27 implanted participants (63% male, aged 55.9±12.0 years, body mass index (BMI) 27.4±3.0 kg·m-2) completed the protocol. At 6 months BMI was unchanged (p=0.85); AHI decreased from 23.7±12.2 to 12.9±10.1 events·h-1, a mean change of 10.8 events·h-1 (p<0.001); and ODI decreased from 19.1±11.2 to 9.8±6.9 events·h-1, a mean change of 9.3 events·h-1 (p<0.001). Daytime sleepiness (Epworth Sleepiness Scale; p=0.01) and sleep-related quality of life (Functional Outcomes of Sleep Questionnaire-10; p=0.02) both improved significantly. The number of bed partners reporting loud, very intense snoring, or leaving the bedroom due to participant snoring decreased from 96% to 35%. 91% of participants reported device use >5 days per week, and 77% reported use for >5 h per night. No device-related serious adverse events occurred during the 6-month post-implantation period. CONCLUSIONS: Bilateral HNS using the Genio™ system reduces OSA severity and improves quality of life without device-related complications. The results are comparable with previously published HNS systems despite minimal implanted components and a simple stimulation algorithm.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References